Skip to main content
. Author manuscript; available in PMC: 2022 Jan 27.
Published in final edited form as: Cell. 2022 Jan 20;185(2):299–310.e18. doi: 10.1016/j.cell.2021.12.023

Figure 1. A longitudinal cohort of DCIS patients with or without subsequent invasive relapse.

Figure 1.

(A) Schematic of the tumor stages and patient sample numbers profiled in this study, including normal breast tissue, primary DCIS, and ipsilateral IBC relapses; 9/12 IBC samples were paired with primary DCIS samples.

(B) Primary DCIS samples consisted of two outcome groups: progressors, who recurred with ipsilateral invasive disease with a median of 9.1 years, and non-progressors, who never recurred within a median follow-up of 11.4 years.